2025
SJR Q2
JCR Q3 · 2,1
OA
92 eşleşen makale
SCIE
Dergi ayrıntısı
Kidney and Blood Pressure Research
- Yayıncı
- S. Karger AG
- Ülke
- Switzerland · Western Europe
- Tür
- journal
- ISSN
-
1420409614230143
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,646
- Quartile Q2
- H-Index 67
- Atıf/yayın 2,03
- Doküman (3y) 254
- Atıf (3y) 592
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,1
- 5Y JIF 2,4
- JCI 0,63
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cardiology and Cardiovascular Medicine Q2
- Nephrology Q2
Alanlar
- Medicine
WoS kategorileri
- Physiology | Urology & Nephrology | Peripheral Vascular Diseases
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,646 | 2,1 | 2,4 | 0,63 | Q2 | 67 |
| 2024 | Q2 | Q2 | 0,728 | 2,1 | 2,4 | 0,71 | Q2 | 64 |
| 2023 | Q2 | Q2 | 0,674 | 2,3 | 2,5 | 0,75 | Q2 | 64 |
| 2022 | Q2 | Q2 | 0,658 | 2,8 | 2,7 | 0,68 | Q2 | 64 |
| 2021 | Q2 | Q2 | 0,707 | 3,1 | 3,2 | 0,7 | Q2 | 64 |
| 2020 | Q2 | Q3 | 0,806 | 2,7 | 2,7 | 0,64 | Q2 | 64 |
| 2019 | Q2 | Q3 | 0,725 | 1,9 | 2,1 | 0,69 | Q2 | 64 |
| 2018 | — | Q2 | — | 2,1 | 2 | 0,73 | Q2 | — |
| 2017 | Q2 | Q2 | 0,54 | 3 | 2,3 | 0,91 | Q1 | 64 |
| 2016 | Q2 | Q2 | 0,75 | 3,1 | 2,5 | — | — | 64 |
| 2015 | Q2 | Q2 | 0,634 | 2,9 | 2,2 | — | — | 64 |
| 2014 | Q2 | Q2 | 0,56 | 2,1 | 1,8 | — | — | 64 |
| 2013 | Q2 | Q3 | 0,654 | 1,8 | 1,6 | — | — | 64 |
| 2012 | Q2 | Q3 | 0,556 | 1,6 | 1,6 | — | — | 64 |
| 2011 | Q2 | Q3 | 0,617 | 1,5 | 1,5 | — | — | 64 |
| 2010 | Q2 | Q3 | 0,765 | 1,5 | 1,5 | — | — | 64 |
| 2009 | — | Q3 | — | 1,7 | 1,6 | — | — | — |
| 2008 | — | Q4 | — | 1,3 | 1,4 | — | — | — |
| 2007 | — | Q4 | — | 1,1 | 1,3 | — | — | — |
| 2006 | — | Q2 | — | 1,9 | — | — | — | — |
| 2005 | — | Q2 | — | 2,4 | — | — | — | — |
| 2004 | — | Q3 | — | 1,1 | — | — | — | — |
| 2003 | — | Q3 | — | 1 | — | — | — | — |
| 2002 | — | Q3 | — | 1 | — | — | — | — |
| 2001 | — | Q2 | — | 1,9 | — | — | — | — |
| 2000 | — | Q2 | — | 1,4 | — | — | — | — |
| 1999 | — | Q3 | — | 0,7 | — | — | — | — |
| 1998 | — | Q3 | — | 0,8 | — | — | — | — |
| 1997 | — | Q3 | — | 0,6 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 57/100 |
| 2025 | PHYSIOLOGY | SCIE | Q3 | Q4 | 62/89 |
| 2025 | UROLOGY & NEPHROLOGY | SCIE | Q3 | Q2 | 70/134 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 53/98 |
| 2024 | PHYSIOLOGY | SCIE | Q3 | Q3 | 51/87 |
| 2024 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 62/133 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 44/96 |
| 2023 | PHYSIOLOGY | SCIE | Q3 | Q3 | 44/85 |
| 2023 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 51/126 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 38/68 |
| 2022 | PHYSIOLOGY | SCIE | Q2 | Q3 | 39/79 |
| 2022 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 40/88 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 39/67 |
| 2021 | PHYSIOLOGY | SCIE | Q2 | Q3 | 37/81 |
| 2021 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 39/90 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 42/65 |
| 2020 | PHYSIOLOGY | SCIE | Q3 | Q3 | 45/81 |
| 2020 | UROLOGY & NEPHROLOGY | SCIE | Q3 | Q2 | 51/89 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 46/65 |
| 2019 | PHYSIOLOGY | SCIE | Q3 | Q3 | 54/81 |
| 2019 | UROLOGY & NEPHROLOGY | SCIE | Q3 | Q2 | 52/85 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 41/65 |
| 2018 | PHYSIOLOGY | SCIE | Q3 | Q3 | 52/81 |
| 2018 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q2 | 37/80 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 27/65 |
| 2017 | PHYSIOLOGY | SCIE | Q2 | Q2 | 29/83 |
| 2017 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q1 | 21/76 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 27/63 |
| 2016 | PHYSIOLOGY | SCIE | Q2 | — | 25/84 |
| 2016 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 21/77 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 29/63 |
| 2015 | PHYSIOLOGY | SCIE | Q2 | — | 28/83 |
| 2015 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 20/77 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 42/60 |
| 2014 | PHYSIOLOGY | SCIE | Q3 | — | 46/83 |
| 2014 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 30/78 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 44/65 |
| 2013 | PHYSIOLOGY | SCIE | Q3 | — | 51/81 |
| 2013 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 40/77 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 44/68 |
| 2012 | PHYSIOLOGY | SCIE | Q3 | — | 54/80 |
| 2012 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 42/73 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 49/68 |
| 2011 | PHYSIOLOGY | SCIE | Q4 | — | 62/79 |
| 2011 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 48/73 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 46/68 |
| 2010 | PHYSIOLOGY | SCIE | Q4 | — | 59/78 |
| 2010 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 43/69 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 39/61 |
| 2009 | PHYSIOLOGY | SCIE | Q3 | — | 51/75 |
| 2009 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 37/63 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 43/56 |
| 2008 | PHYSIOLOGY | SCIE | Q4 | — | 57/74 |
| 2008 | UROLOGY & NEPHROLOGY | SCIE | Q4 | — | 43/57 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 41/54 |
| 2007 | PHYSIOLOGY | SCIE | Q4 | — | 61/78 |
| 2007 | UROLOGY & NEPHROLOGY | SCIE | Q4 | — | 44/55 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 31/52 |
| 2006 | PHYSIOLOGY | SCIE | Q3 | — | 41/78 |
| 2006 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 24/55 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 21/51 |
| 2005 | PHYSIOLOGY | SCIE | Q2 | — | 33/75 |
| 2005 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 14/51 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 37/51 |
| 2004 | PHYSIOLOGY | SCIE | Q4 | — | 58/74 |
| 2004 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 35/52 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 35/52 |
| 2003 | PHYSIOLOGY | SCIE | Q3 | — | 55/74 |
| 2003 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 32/49 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 35/52 |
| 2002 | PHYSIOLOGY | SCIE | Q4 | — | 58/73 |
| 2002 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 31/47 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 22/50 |
| 2001 | PHYSIOLOGY | SCIE | Q2 | — | 28/74 |
| 2001 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 16/44 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 26/45 |
| 2000 | PHYSIOLOGY | SCIE | Q3 | — | 39/76 |
| 2000 | UROLOGY & NEPHROLOGY | SCIE | Q2 | — | 21/43 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 36/44 |
| 1999 | PHYSIOLOGY | SCIE | Q4 | — | 56/74 |
| 1999 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 28/45 |
| 1998 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 25/39 |
| 1998 | PHYSIOLOGY | SCIE | Q3 | — | 46/67 |
| 1998 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 25/41 |
| 1997 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 27/38 |
| 1997 | PHYSIOLOGY | SCIE | Q4 | — | 51/65 |
| 1997 | UROLOGY & NEPHROLOGY | SCIE | Q3 | — | 26/37 |